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Transforming Growth Factor 1 in the Pathogenesis of
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Lesson From Twins and Triplets Discordant for the Disease
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Objective. Clinical evidence and experimental ev-
idence suggest that anti-Ro/La autoantibodies are nec-
essary but not sufficient for the development of congen-
ital complete heart block (CCHB). Maternal, fetal, and
environmental factors may also contribute to heart
damage in CCHB. The aim of our study was to investi-
gate polymorphisms of transforming growth factor 1
(TGF1) and tumor necrosis factor  (TNF) genes in
twins and triplets discordant for CCHB whose mothers
are anti-Ro/La positive.
Methods. We studied 2 families in which 1 of the
mothers gave birth to triplets and the other gave birth to
twins. Only 1 child in each family was affected by
CCHB, although 1 of the triplets had incomplete heart
block. We analyzed TNF and TGF1 polymorphisms
in the 2 babies with CCHB and their siblings. TNF
polymorphisms at the promoter region and TGF1
polymorphisms at codons 10 and 25 were determined
using polymerase chain reaction–restriction fragment
length polymorphism analysis. In addition, the produc-
tion of TGF1 and TNF by resting or mitogen-
stimulated peripheral blood mononuclear cells in cell
culture supernatants was evaluated by enzyme-linked
immunosorbent assay.
Results. The profibrotic TGF1 genotype was
detected in the twin with CCHB but not in the healthy
twin, while all of the triplets displayed the same TGF1
genotype at codon 10. Peripheral blood mononuclear
cells from the children with CCHB displayed higher
spontaneous and mitogen-stimulated TGF1 secretion
than was observed in their siblings. No differences
regarding TNF polymorphisms and secretion of TNF
were observed.
Conclusion. The results of this study suggest that,
besides anti-Ro/La autoantibodies, a fetal profibrotic
response might contribute to the development of CCHB,
but additional pathogenic mechanism(s) are also likely
to play a role.
Neonatal lupus is a model of passively acquired
autoimmune disease; its major clinical manifestation is
congenital complete heart block (CCHB) (1,2). In al-
most all cases, CCHB in the absence of congenital
cardiac malformations is linked to the presence of
autoantibodies against the nuclear antigens SSA/Ro and
SSB/La. Results of numerous experimental studies sup-
port the evidence that the clinical manifestations of
neonatal lupus not only are associated with but also are
causally related to the presence of these autoantibodies.
However, it is not known why only a minority of mothers
with anti-Ro and anti-La antibodies give birth to an
affected child (3) nor why heart block almost always
affects only the fetus and not the mother. Moreover, the
disease discordance in twins, both monozygotic and
dizygotic, is intriguing (4). It has therefore been sug-
gested that the presence of anti-Ro/La antibodies rep-
resents a condition that is necessary but not sufficient for
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disease development. It has been hypothesized that
maternal, fetal, and environmental factors are also con-
tributory (5).
Cytokines that lead from inflammation to fibro-
sis, such as tumor necrosis factor  (TNF) and trans-
forming growth factor  (TGF), have been suggested
to be involved in the pathogenesis of CCHB. Polymor-
phisms of these cytokines were evaluated in a recent
large study (6), and a significantly increased frequency of
the308A (high producer) allele of TNF was observed
in all of the patients with neonatal lupus, independently
of the clinical manifestations. In contrast, the frequency
of the TGF polymorphism Leu-10 (which is associated
with increased fibrosis) was significantly higher in chil-
dren with CCHB than in unaffected offspring and
controls. This finding, together with the demonstration
that macrophages secrete high levels of TGF when
cocultured with apoptotic human fetal cardiocytes sen-
sitized by anti-Ro antibodies, suggests that both proin-
flammatory and profibrotic cytokine environments in
the fetus might be factors favoring the occurrence of
CCHB (7). In the current study, we tested this hypothe-
sis in twins and triplets discordant for CCHB.
PATIENTS AND METHODS
Patients. We recently encountered 2 families in which
1 mother gave birth to triplets, and the other mother gave birth
to twins. Of the triplets, 1 had CCHB, the second had
minor-degree (i.e., incomplete) heart block, and the third child
was healthy. In the other family, 1 of the twins had CCHB, and
the other twin was healthy (8,9). Informed consent was ob-
tained from the mothers, and the protocol was approved by the
ethics committee of the treating center (Clinica Pediatrica,
Milan, Italy).
Polymorphisms and in vitro production of cytokines by
peripheral blood mononuclear cells (PBMCs). TNF poly-
morphisms at the promoter region and TGF1 polymorphisms
at codons 10 and 25 were determined using polymerase chain
reaction–restriction fragment length polymorphism analysis, as
previously described (6). The DNA amplification primers were
as follows: for TNF, 5-AGGCAATAGGTTTGAGGGT-
CAT-3 (forward) and 5-ACACTCCCCATCCTCCCTG-
CTC-3 (reverse); for TGF, 5-TTCCCTCGAGGCCCTCC-
TA-3 (forward) and 5-GCCGCAGCTTGGACAGGATC-3
(reverse). Amplified DNA (4 l) was digested in a 10-l
reaction mixture using buffer and temperatures recommended
by the manufacturer. The enzymes used were as follows: for
TNF, Nco I; for codon 10 of TGF, Msp A1I; and for codon
25 of TGF, Fse I (all from New England Biolabs, Ipswich,
MA). The analysis was performed using DNA from the
triplets, the twins, and a healthy control baby.
Isolated PBMCs were cultured for 48 hours in a
humidified atmosphere with 5% CO2, in medium alone or in
the presence of phorbol myristate acetate (5 ng/ml) plus
ionomycin (500 ng/ml) (Sigma-Aldrich, St. Louis, MO). TNF
and TGF1 levels in cell culture supernatants were determined
by enzyme-linked immunosorbent assay, according to the
manufacturers’ instructions (BioSource, Nivelles, Belgium,
and R&D Systems, Minneapolis, MN, respectively).
RESULTS
Both mothers were positive for anti–52-kd Ro,
anti–60-kd Ro, and anti-La. The mother of the triplets
was asymptomatic, and the mother of the twins had
subacute cutaneous lupus erythematosus. Despite the
presence of these pathogenic autoantibodies, only 1 of
the triplets and 1 of the twins had CCHB.
In the family with twins, the TGF1 profibrotic
genotype was identified in the child with CCHB but not
in the healthy sibling (Figure 1). In the family with
triplets, all 3 siblings showed the same TGF1 genotype
at codon 10. No differences in the TGF1 polymorphism
at codon 25 were observed between patients with CCHB
and their siblings (data not shown).
The 2 children with CCHB displayed both spon-
taneous and mitogen-stimulated secretion of TGF1,
the level of which was higher than that observed in their
siblings. Interestingly, the level of TGF1 secretion was
lowest in the child without the profibrotic TGF1 poly-
morphism (Figure 2). All of the children displayed the
presence of the 308A TNF allele, and no differences
Figure 1. Transforming growth factor 1 Leu-10 polymorphisms in
triplets (lanes 1, 2, and 3), twins (lanes 4 and 5 [lane 4 represents the
twin with congenital complete heart block]), and a healthy baby (lane
6). The profibrotic genotype is associated with a double DNA line.
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in TNF secretion by PBMCs between CCHB patients
and their siblings were observed (data not shown).
The age of the children at the moment of blood
drawing was 30 months for the triplets and 20 months for
the twins. We chose not to perform the cytokine pro-
duction experiments during the first year of life, because
these babies had been exposed in utero to maternal
dexamethasone treatment, which was given to the moth-
ers because of the presence of CCHB and could have
temporarily influenced the immune systems of the new-
borns.
DISCUSSION
Besides anti-Ro/La autoantibodies, additional
maternal, fetal, and environmental factors have all been
implicated as contributing to the development of CCHB
(5). For example, a diverse production of cytokines has
been suggested to play a possible role in explaining the
differences in disease expression. In this regard, histo-
logic evaluation of hearts affected by CCHB raised the
possibility of a pathogenic role of TNF, as suggested by
the increased presence of this cytokine in tissue lesions
(6). It has been hypothesized that a higher prevalence of
TNF polymorphisms associated with increased cyto-
kine production could have a role. However, Clancy et al
(6) did observe a higher frequency of the 308A (high
producer) allele of TNF in 88 children and 74 mothers
from the Research Registry for Neonatal Lupus, but
without any association with CCHB. Our data for both
triplets and twins did confirm the lack of a correlation
between TNF polymorphisms and CCHB; moreover,
levels of this cytokine in cell supernatants were not
significantly different between patients with CCHB and
their siblings.
The contribution of TGF to CCHB has also
been recently reviewed (10). TGF is a multifunctional
cytokine that modulates the proliferation and differen-
tiation of many cell types, and it is considered to play a
critical role in fibrotic conditions (11). The human gene
encoding TGF is located on chromosome 19q13 and is
highly polymorphic. Two of its 5 known polymorphisms,
i.e., those at positions 869 and 915, which change codon
10 (T or C, Leu3Pro) and codon 25 (G or C,
Arg3Pro), are associated with interindividual variation
in TGF production. For both polymorphisms, the
alleles encoding proline are generally associated with
lower TGF synthesis in vitro and in vivo. The genetic
and histologic study by Clancy et al convincingly linked
TGF to the pathogenesis of CCHB (6). In fact, the
contribution of TGF polymorphism Leu-10 was signif-
icantly higher in children with CCHB than in unaffected
offspring and controls, while there were no significant
differences between controls and other groups of pa-
tients with neonatal lupus (i.e., those without CCHB).
For TGF polymorphism Arg-25, there were no signif-
icant differences between neonatal lupus groups and
controls.
In the present study, we corroborated these find-
ings in the family with twins but not in the family with
triplets. Interestingly, PBMCs from the 2 patients with
CCHB displaying the profibrotic genotype secreted lev-
els of TGF1 in vitro that were higher than those of
their siblings, in either resting or mitogen-stimulated
conditions. Although as a whole these findings suggest
that TGF1 secretion might play a role in the pathogen-
esis of CCHB, this is not sufficient to explain the
differences in disease expression.
Additional fetal factors have been reported. For
example, the persistent presence of maternal cells in the
fetal heart (microchimerism) has been suggested to be
involved in the pathogenesis of CCHB by eliciting a
graft-versus-host reaction or an allogenic response that
may induce local inflammatory damage of the atrioven-
tricular cardiac conduction tissue (9,12). Polymorphisms
of the human Fc receptor (FcR) have also been
proposed as representing an additional fetal factor that
is potentially responsible for the development of CCHB
(13). Actually, FcR polymorphisms are known to be
associated with different affinity for the Fc domain of
IgG, affecting in vivo immune complex clearance and
Figure 2. Transforming growth factor 1 (TGF1) secretion by rest-
ing or activated peripheral blood mononuclear cells from patients with
congenital complete heart block (CCHB) and their siblings. A, Cyto-
kine levels in culture supernatants from triplets. The middle column
represents the triplet with incomplete heart block. B, Cytokine levels in
culture supernatants from twins. Values are the mean  3 SD of
triplicate determinations. Unaff  unaffected; PMA-Iono  phorbol
myristate acetate–ionomycin.
358 CIMAZ ET AL
modulating antibody ligation to Fc receptors and their
subsequent downstream effects on the cells (14). We
previously analyzed FcRIIa and FcRIIIb genotyping
in these triplets (15), and the baby with CCHB showed
a His/His-131 genotype for FcRIIa, while the other 2
had a heterozygous Arg/His-131 genotype. Also, the
FcRIIIb NA1/NA2 genotype was observed in the af-
fected child but not in the siblings (NA2/NA2 genotype).
The genotypes in the affected baby, in particular His/
His-131, are known to display higher affinity for IgG and
could have contributed to a stronger activation of phago-
cytes favoring the local inflammatory process in the
atrioventricular conduction tissue.
In conclusion, our findings in a spontaneous in
vivo model confirm that a profibrotic response linked to
increased TGF1 secretion might be involved in the
pathogenesis of CCHB. However, this does not seem to
be the unique fetal factor, and additional mechanisms
are apparently contributory. It is worth noting that we
previously demonstrated a correlation between the pres-
ence of microchimerism and CCHB only in the triplet
family (9), while in the present study we observed a
correlation with TGF1 polymorphisms in the twin
family. Together with our data on FcR genotyping,
these findings suggest not only that a mosaic of mater-
nal, fetal, and possibly environmental factors might be
involved in inducing CCHB, but also that the combina-
tion of such factors might be variable among different
patients.
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